Search this site

Firmus has shelved its planned $5 billion IPO amid market volatility and valuation concerns, highlighting growing investor scrutiny of expensive AI infrastructure projects. One of Australia's most ambitious technology listings has been shelved, delivering another warning about investor confidence in the AI infrastructure boom. Firmus, an AI data-centre operator backed by Nvidia and Blackstone, has abandoned plans to raise more than $5 billion through an initial public offering. The proposed listing would have valued the company at more than $30 billion, despite its limited operating history and substantial expansion costs. Market volatility and concerns about ambitious valuations complicated the offering. Firmus will instead explore alternative financing options. The setback comes as investors increasingly question how quickly enormous AI infrastructure investments can generate sustainable returns. The investor takeaway: Demand for AI computing remains substantial, but enthusiasm alone may no longer be enough to justify aggressive valuations. Financing costs, profitability and execution are becoming increasingly important.

Wall Street faces a critical week as major banks report earnings and fresh inflation data tests investor confidence. Corporate profits and interest rates will be firmly in focus. Wall Street's rally is heading into a crucial test as America's largest banks prepare to kick off third-quarter earnings season. JPMorgan, Goldman Sachs, Citigroup and Wells Fargo are scheduled to report on Tuesday, with Bank of America and Morgan Stanley following Wednesday. Analysts expect S&P 500 earnings to rise more than 30% from a year earlier, setting a high bar for corporate performance. However, rising Treasury yields and persistent inflation concerns are complicating the outlook. Higher borrowing costs could pressure corporate profits and weaken demand for loans. Wednesday's US inflation report will add another major test, potentially shifting expectations for the Federal Reserve's next interest-rate decision. The investor takeaway: Strong earnings could support further market gains, but disappointing results or stubborn inflation may challenge already elevated stock valuations.

Amazon is reportedly considering a $7 billion acquisition of AI startup Decart, putting the potential commercial value of video AI and robotics simulation in focus for shareholders. Amazon could be preparing another major AI purchase. The company is in talks to acquire Decart for around $7 billion, according to a Wall Street Journal report cited by Reuters. The startup develops real-time video AI and simulated environments for training robots and autonomous-driving systems. No agreement has been announced. For Amazon shareholders, the potential appeal is technology that could expand its AI capabilities and create new commercial services. The challenge would be turning an expensive acquisition into products customers consistently pay for. The investor takeaway: Watch for confirmed terms and a clear explanation of how Decart would contribute to Amazon’s revenue. A large purchase price makes commercial execution especially important.

KKR and TotalEnergies are adding a $1.2 billion solar portfolio to their US joint venture, with projects in Texas and Ohio expected to begin operating by early 2027. KKR is expanding its exposure to American power infrastructure. The investment firm and TotalEnergies announced Monday an agreement to add 700 megawatts of solar capacity to their equally owned US joint venture. The three projects, located in Texas and Ohio, carry a combined $1.2 billion enterprise value. They are expected to begin commercial operations by the first quarter of 2027, increasing the venture’s portfolio from 1.4 gigawatts to 2.1 gigawatts. TotalEnergies will continue operating the assets. Completion of the transaction is expected in 2026, subject to customary conditions. For KKR shareholders, the agreement adds another investment in assets capable of generating recurring electricity-sale income. Returns will depend on construction costs, operating performance and the prices secured for that power. The investor takeaway: Watch whether the projects reach operation on schedule and deliver attractive returns on the capital invested.

Airbus has completed a European test flight of Kratos’ Valkyrie drone, advancing a potential growth opportunity for the US defence company while leaving contracts and delivery milestones ahead. Kratos has moved closer to a potential European defence opportunity. Airbus reported Monday that it completed the first European test flight of Kratos Defense’s Valkyrie drone. The partners aim to supply combat-ready aircraft to Germany by 2029, although Airbus’ European mission system was not incorporated into the initial flight. For shareholders in US-listed Kratos, the milestone supports the prospect of selling its technology into another market. The commercial test comes next: securing orders, integrating the required systems and delivering aircraft at a profitable cost. The investor takeaway: Successful testing strengthens the opportunity, but investors should watch for funded contracts before treating potential demand as future revenue.

Veea surged 47% after restoring Nasdaq compliance, with new community and retail agreements adding momentum. Investors now need evidence that deployments can generate meaningful revenue while limiting further dilution. Veea (NASDAQ: VEEA) has cleared a Nasdaq listing hurdle—and its latest AI deals give investors something new to watch. Shares surged 47% to $5.70 on Friday, October 9, with roughly 83.6 million shares traded. The rally followed Veea’s announcement that board and committee changes had restored full Nasdaq compliance. The company makes hardware and software that run AI locally in stores and communities, helping operators process camera and sensor data closer to its source. Recent agreements include a smart community project covering 220 residential properties and a planned rollout across 1,000 unattended stores, starting with up to 50 locations. The opportunity is clear. The financial pressure is too. Veea reported approximately $400,000 in first-half revenue and $887,000 in unrestricted cash at June 30, while operating losses continued. Further share sales could dilute existing investors. What we’re watching: Paid deployments, recognised revenue and the next cash update. Can Veea turn its commercial momentum into meaningful income before needing more capital? This is not an investment recommendation. Image caption: Worthy Endeavor AI-generated illustration showing a Veea-branded concept edge computing hub in a smart community. This is not a company photograph or verified product depiction.

CCC shares jumped after reports of advanced takeover talks with GTCR and Elliott, leaving investors focused on a potential offer price and the risk that negotiations fail. Takeover interest has put CCC Intelligent Solutions in the spotlight. GTCR and Elliott Investment Management are in advanced talks to acquire the software provider, Reuters reported Friday evening. CCC shares rose around 13% in extended trading. The company supplies software to auto insurers, repair shops and other automotive businesses. No final agreement or financial terms had been announced in the reporting checked. For shareholders, the next question is how much a buyer would offer—and how much optimism the share price already reflects. The investor takeaway: A confirmed bid could establish a clearer valuation. If negotiations stall, investors would again need to judge CCC primarily on its earnings and growth prospects.

Citi is pushing to resolve longstanding regulatory orders, a potential milestone that could free resources for growth and strengthen investor confidence in the bank’s wider turnaround strategy. Citigroup’s next growth opportunity may begin with clearing its regulatory backlog. The bank is working towards resolving longstanding US regulatory orders, Reuters reported Monday. CEO Jane Fraser says around 90% of the required work is complete, but regulators decide when the orders can be lifted. For shareholders, that decision could become an important test of Citi’s turnaround. Reducing the resources absorbed by remediation could give management more room to focus on customers, growth and profitability. Completing internal work, however, does not guarantee a quick regulatory sign-off. The investor takeaway: Watch for formal approval and evidence that progress translates into better financial performance. Those would provide stronger support for the turnaround than completion estimates alone.

Delta Opens the Door & Cuts the Ribbon on America’s First New Fluorspar Lumps Plant. Federal, state and industry leaders will gather in Utah on October 9 as a fully permitted mine and a purpose-built plant finally sit on the same domestic supply chain. Let that sink in! On Friday morning in Delta, Utah, a ribbon will be cut on something the United States has not had for a generation: a working, company-built path from a domestic fluorspar mine to finished metallurgical product. Ares Strategic Mining Inc. (CSE: ARS; OTCQX: ARSMF; FRA: N811) will host an official ceremony at 11:00 a.m. on October 9, 2026, at the ARES Processing Facility, formally opening the company’s new Lumps Plant. The plant takes run-of-mine ore from the fully permitted Lost Sheep Mine, in the Spor Mountain district of Juab County, and turns it into industry-ready metallurgical-grade fluorspar metspar - the flux steelmakers and aluminum producers have long had to import. Now is the last chance to get onboard with this stock before it starts to fly. After this extra exposure and the upcoming NASDAQ listing, this stock is set to soar. Why now? Ore is already moving. Trucks are hauling Lost Sheep material into Delta, live feed is entering the circuit, and the operations team is tuning the plant to the ore it is actually mining. Friday is the public marker of that shift, from years of permitting, engineering and construction to a mine-to-plant operation on American ground. “We have reached the moment when years of permitting, mine development, engineering, construction and financing have become a working U.S. mine-to-plant operation,” said James Walker, President and CEO. “Ore is being mined, trucked to our facility and run through the plant. Friday gives us the opportunity to recognize the team, shareholders, public-sector partners and local community who helped turn that plan into physical infrastructure. For Ares, this is the beginning of an entirely new chapter.” Who is in the room? An unbelievable guest list! Confirmed attendees include U.S. Representative Mike Kennedy Carson Brown from the office of U.S. Senator John Curtis; Utah State Senator David P. Hinkins, Emy Lesofski, Director of the Utah Office of Energy Development; Dana Dean, Acting Director of the Utah Division of Oil, Gas and Mining; James Walker, President and CEO of Ares Strategic Mining; and Peter Godart, President and CEO of Found Industries. Scheduled speakers are Peter Godart, Representative Mike Kennedy, James Walker and a federal government representative. Ares is also coordinating attendance from the U.S. Department of Defense, the Department of Energy and the Defense Logistics Agency, with final names still to be announced. The guest list is the point. A lumps plant in Millard County only matters if Washington, the state capitol and the customers who consume flux all see the same asset. Utah wrote the project into the statute book The ceremony will also mark the state’s role in getting the facility built. In the 2025 General Session, the Utah Legislature broadened the legal definition of a “throughput infrastructure project” so that it covers infrastructure required to extract and process critical minerals. Ares subsequently received an $11 million state-supported loan through the Utah Community Impact Board to advance its Utah operations. “The support we have received in Utah has allowed Ares to move from plans and engineering drawings to mine development, processing infrastructure and physical production,” Walker said. “We are proud to celebrate this milestone in Delta with many of the people and organizations that have supported the project, and we look forward to showing what has been built.” Lost Sheep itself is 100 percent owned: 5,982 acres and 353 claims, about 214 kilometres southwest of Salt Lake City, fully permitted, including a mining plan approved by the Bureau of Land Management. An NI 43-101 technical report identified extensive high-grade fluorspar with low levels of impurities. Lumps first, acidspar next The Lumps Plant is the first processing piece of a wider Utah plan, not the last. Ares is also advancing a complementary acidspar flotation plant, intended to produce higher-purity acid-grade fluorspar for chemical, technology, energy and strategic-material uses. Friday opens the metallurgical gate. The flotation plant is the next one. With mining underway, ore on the road to Delta and the lumps circuit in live-material operations, the ribbon cutting is the formal public line between development and an operating mine-and-processing business. We're excited to watch this won, and its our Worthy Endeavor of the Week, 5th October 2026. Not financial advice. Do your own research before investing. Promotional article.

60 Degrees Pharmaceuticals has a hospital study that will not finish enrollment, and a January date for the answer it did not give on Tuesday. On 6 October 2026 the Washington company said it will end enrollment in its randomized trial of tafenoquine in patients hospitalized with severe babesiosis at 30 subjects, three short of the 33 the data-safety board had recommended. The study stays blinded. Primary and secondary results are planned for January 2027, when the company also intends to ask the FDA for a pre-sNDA meeting. The board found no safety issues. It did not say whether the drug worked. 60 Degrees sells ARAKODA, the tafenoquine tablet approved in 2018 for malaria prevention, in the United States and as a related brand in Australia. Babesiosis is a different use. The parasite infects red blood cells, often travels with Lyme disease, and has no FDA-approved treatment. The hospital trial, NCT06207370, tests oral tafenoquine plus standard care against placebo plus standard care. Sites include Tufts, Rhode Island Hospital, Yale, Brigham and Women’s, and Westchester Medical Center. Nasdaq: SXTP closed Tuesday at $1.11, down 22.92%, and Stock Analysis put the market value at about $3.90 million. ChartExchange showed volume of about 2.43 million shares against a 30-day average near 97,000. The release had been previewed as an interim look. What arrived was a decision to stop early for seasonality and limited added power, not an efficacy number. The opening is real because the company already has an approved molecule and a disease with no labeled therapy. The gap is that case reports and three expanded-access molecular cures are not a hospital trial result. A January meeting request is not an approval path. The company’s own June quarter filing, as summarized from the 10-Q, showed about $1.0 million of cash, heavy operating cash use, and a going-concern warning. A September presentation was reported to put the runway only into early October. Tuesday’s release did not refresh that figure. What we are watching is whether January’s unblinding shows a difference on time to clinical resolution, and whether the company can fund the wait. The question for management is simple: what cash is on hand after 6 October, and what financing, if any, is required before the readout? Sources: GlobeNewswire, 6 October 2026; company investor news page; Stock Analysis; ChartExchange; StockTitan summary of the June 2026 Form 10-Q. No investment recommendation. Worthy Endeavor has no position to disclose in this note.

Genmab shares rose after its AbbVie-partnered lymphoma treatment delivered positive Phase 3 results. Expansion into newly diagnosed patients could create a larger revenue opportunity, subject to regulatory approval. Genmab’s European shares climbed 7.6% on Tuesday morning after the company and AbbVie announced positive late-stage results for a lymphoma treatment combination. Their Phase 3 study found that adding epcoritamab to standard R-CHOP treatment reduced the risk of disease progression or death by 51% compared with R-CHOP alone in the patients studied. The trial involved people with newly diagnosed diffuse large B-cell lymphoma. The companies said the treatment’s safety profile was generally consistent with the known profiles of the medicines involved. A potential larger market For investors, the opportunity lies in expanding epcoritamab’s use to patients beginning treatment. Successful expansion could increase its commercial reach and strengthen the partners’ cancer portfolios. However, the combination is not yet approved for this newly diagnosed population. Regulatory decisions remain a necessary step before the trial results can translate into additional sales. The results strengthen the growth case, while leaving approval and eventual uptake as the next tests.

A reported $3 billion US manufacturing commitment puts Becton Dickinson’s spending plans in focus. Investors need company details on timing, cash-flow requirements and the expected returns from additional capacity. Becton Dickinson has agreed to invest $3 billion in US medical-product manufacturing, President Donald Trump said on Monday. According to the announcement, more than $1 billion would go to Nebraska, including production of needles using American steel. BD had not immediately responded to Reuters’ request for comment when its report was published. The spending timetable matters For shareholders, additional manufacturing capacity could improve supply reliability and support future sales. The near-term question is how much cash the expansion requires and when the company expects a return. Capital spending can weigh on free cash flow before new facilities contribute meaningfully to earnings. The investment’s value will therefore depend on demand, production efficiency and how quickly capacity becomes operational. Company details are needed to establish the timetable and whether the reported figure includes previously announced spending. Until then, investors have a headline investment amount, but limited information for assessing its effect on BD’s finances.